

Akashi Y, <u>Okamoto I</u> , Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K, Nakagawa K.	Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.	Br J Cancer.	98(4)	749-755	2008
Takezawa k, <u>Okamoto I</u> , Fukuoka J, Tanaka K, Kaneda H, Uejima H, Yoon H, Imakita M, Fukuoka M, Nakagawa K.	Large cell neuroendocrine carcinoma of the mediastinum with $\alpha$ -fetoprotein production.	Journal of Thoracic Oncology.	3(2)	187-189	2008
Okabe T, <u>Okamoto I</u> , Tsukioka S, Uchida J, Iwasa T, Yoshida T, Hatashita E, Yamada Y, Satoh T, Tamura K, Fukuoka M, Nakagawa K.	Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.	Mol Cancer Ther.	7(3)	599-606	2008
<u>Okamoto I</u> .	Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan.	Int J Clin Oncol.	13	112-116	2008
<u>Okamoto I</u> , Nishimura T, Miyazaki M, Yoshioka H, Kubo A, Takeda K, Ebi N, Sugawara S, Katakami N, Fukuoka M, Nakagawa K.	Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505.	Clin Cancer Res.	14(16)	5250-5254	2008
TakezawaK, <u>Okamoto I</u> , Fukuoka M, Nakagawa K.	Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis.	Journal of Thoracic Oncology.	3(9)	1073-1075	2008

Tamura K, <u>Okamoto I</u> , Kashii T, Negoro S, Hirashima T, Kudoh S, Ichinose Y, Ebi N, Shibata K, Nishimura T, Katakami N, Sawa T, Shimizu E, Fukuoka J, Satoh T, Fukuoka M.	Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).	British Journal of Cancer.	98 (5)	907-914	2008
Iwasa T, <u>Okamoto I</u> , Suzuki M, Nakahara T, Yamanaka K, Hatashita E, Yamada Y, Fukuoka M, Ono K, Nakagawa K.	Radiosensitizing effect of YM155, a novel small molecule urvivin suppressant, in non-small cell lung cancer cell lines.	Clinical Cancer Res.	14 (20)	6496-6504	2008
Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine SJ, <u>Okamoto I</u> , Nakanishi Y; Lung Oncology Group in Kyushu, Japan.	A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.	J Thorac Oncol.	3 (10)	1166-1171	2008
Morinaga R, <u>Okamoto I</u> , Fujita Y, Arao T, Sekijima M, Nishio K, Ito H, Fukuoka M, Kadota J, Nakagawa K.	Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer.	Cancer Science.	99 (2)	2455-2460	2008
Yoshida T, <u>Okamoto I</u> , Iwasa T, Fukuoka M, Nakagawa K.	The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF.	FEBS Lett.	582 (30)	4125-4130	2008